Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Various trials within the small cell lung cancer space were brought to light following recent data, impacting how patients will be treated in the future.

IMDELLTRA is a first-in-class targeted immunotherapy engineered by Amgen. A pharmacist filling a prescription for a complex drug developed by the company.

AMGN's Imdelltra slashes lung cancer death risk by 40% in Phase III, extending survival by over five months compared to chemotherapy.

IMDELLTRA ® (tarlatamab-dlle) is indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.

Administer IMDELLTRA ® in an appropriate health care facility equipped to monitor and manage CRS. Ensure patients are well hydrated prior to administration of IMDELLTRA ®.

Administer IMDELLTRA ® according to the step-up dosing schedule in the IMDELLTRA ® PI (Table 1) to reduce the incidence and severity of CRS.

Administer IMDELLTRA ® according to the step-up dosing schedule in the IMDELLTRA ® PI (Table 1) to reduce the incidence and severity of CRS.

IMDELLTRA is a treatment for adult patients with recurrent or refractory extensive small cell lung cancer who have received second-line treatment or more, including chemotherapy.